Two drugs taken together can sometimes lead to outcomes that largely deviate from the effect of the separated compounds – a fact well known from warnings on patient information leaflets. However, while doctors strongly advice against unsupervised mixing of drugs, the synergy of two combined pharmaceuticals assessed in an experimental setting can reveal completely new therapeutic options. Nevertheless, finding a novel combination of drugs for a given disease within the more than 30,000 drug products approved by the regulatory agencies was hitherto a big challenge for scientists.
To facilitate systematic screening for synergistic interactions of drugs, CeMM PI Stefan Kubicek and his colleagues established a collection of 308 compounds (CeMM Library of Unique Drugs, CLOUD) that effectively represent the diversity of structures and molecular targets of all FDA-approved chemical entities. Moreover, the scientists proved the potential of the CLOUD with CeMM´s highly automated chemical screening platform by identifying a novel synergistic effect of two drugs (flutamide and phenprocoumon (PPC)) on prostate cancer cells. The results of Kubicek´s team with Marco Licciardello as first author were published in Nature Chemical Biology(DOI:10.1038/nchembio.2382)
For the establishment of the CLOUD, a clever series of condensation steps was necessary: the CeMM scientists first determined and extracted 2171 unique active pharmaceutical ingredients from the database, discarding all products with identical compounds. Next, they removed large macromolecules like antibodies as well as salt fragments, and discarded all molecules that exert their biological effects through mechanisms other than protein-ligand interactions, are not used to treat diseases or are found only in topical products.
With the remaining 954 systemically active small molecules (STEAM collection), the work had just begun: in order to create a comprehensive collection of compounds that fits on a standard 384-well screening plate, the researchers appended biological activities to all drugs with known molecular targets and grouped them into 176 classes of similar structure and activity. With a sophisticated clustering algorithm, 239 representative drugs were selected from those classes. Combined with 34 drugs with unknown target and 35 active forms of prodrugs (that otherwise need to be metabolized to become active), 308 compounds were selected in total for the CLOUD – the world´s first library representing all FDA-approved chemical entities including the active form of prodrugs.
To put the combinatorial screen with the CLOUD to the test, Kubicek’s group investigated the effect of pairwise combinations of CLOUD compounds on the viability on KBM7 leukemia cells, a cell line well suited for drug experiments. Using a dose chosen for each compound individually based on the clinically relevant maximum plasma concentration, the scientists found a strong synergistic interaction between flutamide, a drug approved for the treatment of prostate cancer, and phenprocoumon (PPC), an anti-thrombosis compound. In combination, flutamide and PPC efficiently killed the cancer cells.
After identifying the androgen receptor (AR) as molecular target of the synergistic interaction, the scientists tried the drug combination on prostate cancer cells known to be hard to treat – and hit the bulls eye. “The combination induced massive cell death in prostate cancer cells. We then went back to the entire approved drug list, and indeed, we could show that all drugs from the clusters that flutamide and phenprocoumon represent synergize. Thereby we validated the reductionist concept underlying the CLOUD library,” Stefan Kubicek explains.
With their experiments, Kubicek´s team in collaboration with scientists from the Medical University of Vienna, the Uppsala University, Enamine Kiev and the Max Planck Institute for Informatics in Saarbrücken proved that the CLOUD is the ideal set of compounds to develop screening assays and discover new applications for approved active ingredients. At CeMM, a number of key discoveries on new applications for approved drugs have already been made with the CLOUD. Furthermore, as shown in the current issue of Nature Chemical Biology, the CLOUD is ideal for finding new drug combinations. “In view of these successes, I would predict that this set of compounds will become world standard for all screening campaigns”, Stefan Kubicek emphasizes.
The Latest on: Synergistic interactions of drugs
The Truth About Terps
on July 9, 2018 at 4:07 am
Before we get back to Dr. Russo’s work and attempt to more fully understand the interactions between terpenes and cannabinoids ... leading to theories about the synergistic effects that terpenes and c... […]
Allergan/Tobira And Cenicriviroc: The Overlooked And Misunderstood Immune Modulatory Anti-NASH Drug Candidate
on July 6, 2018 at 11:05 am
Let the truth be told that no one really knows if and how a dual anti-NASH drugs combination trial will work to potentially induce synergistic or additive benefits ... of immune and non-immune cells t... […]
Food Additives and Drugs Change Antibiotic Effectiveness
on July 5, 2018 at 6:34 am
Results from the screen suggested that of all the interactions identified, about 500 drug combinations improved antibiotic outcome. However, there were 50% more antagonistic, than synergistic interact... […]
Compugen Announces FDA Clearance of IND Application for COM701, a First-in-class Immuno-Oncology Therapeutic Antibody
on July 2, 2018 at 4:35 am
COM701 is a first-in-class drug opportunity that was developed by Compugen from ... a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with its li... […]
The global biosimulation market size is expected to reach USD 3.77 billion by 2024
on June 28, 2018 at 12:45 pm
NEW YORK, June 28, 2018 /PRNewswire/ -- Biosimulation Market Size, Share & Trend Analysis Report By Product (Software, Services), By Application (Drug, Development ... and prediction of unfavorable dr... […]
via Google News and Bing News